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Increased albumin and fibrinogen synthesis rate in patients with
chronic renal failure.
Background. Hypoalbuminemia and hyperfibrinogenemia
are frequently observed in patients with chronic renal failure
(CRF) and are both associated with cardiovascular diseases.
The mechanisms responsible for hypoalbuminemia and hyper-
fibrinogenemia in CRF are unknown.
Methods. In the present study, both albumin and fibrinogen
kinetics were measured in vivo in predialysis patients (N  6),
patients on peritoneal dialysis (N  7) and control subjects
(N  8) using l-[1-13C]-valine.
Results. Plasma albumin concentration was significantly lower
in patients on peritoneal dialysis compared to control subjects
(P  0.05). Plasma fibrinogen was significantly increased in
both predialysis patients (P  0.01) as well as patients on
peritoneal dialysis (P  0.001) in comparison to control sub-
jects. In contrast to albumin, fibrinogen is only lost in peritoneal
dialysate and not in urine. The absolute synthesis rates (ASR)
of albumin and fibrinogen were increased in patients on perito-
neal dialysis (ASR albumin, 125  9 mg/kg/day versus 93  9
mg/kg/day, P 0.05; ASR fibrinogen, 45 4 mg/kg/day versus
29  3 mg/kg/day, P  0.01) compared to control subjects.
Albumin synthesis is strongly correlated with fibrinogen syn-
thesis (r 2  0.665, P  0.0001, N  21). In this study, the
observed hypoalbuminemia in patients on peritoneal dialysis
is likely not explained by malnutrition, inadequate dialysis, in-
flammation, metabolic acidosis, or insulin resistance. We specu-
late that peritoneal albumin loss is of relevance.
Conclusion. Synthesis rate of albumin and fibrinogen are
coordinately up-regulated. Both albumin and fibrinogen are
lost in peritoneal dialysis fluid. To compensate protein loss,
albumin synthesis is up-regulated, but the response, in contrast
to predialysis patients, does not fully correct plasma albumin
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concentrations in peritoneal dialysis patients. The increase in
fibrinogen synthesis introduces an independent risk factor for
atherosclerosis, since plasma fibrinogen pool is enlarged.
Hypoalbuminemia is a strong predictor of mortality
and morbidity in patients with chronic renal failure (CRF).
Long-term survival in dialysis is low and half of the
patients die of cardiovascular complications [1–3]. In
particular, low levels of nutritional indices such as albu-
min, prealbumin, and creatinine have been associated with
poor survival in dialysis patients [1, 4, 5]. In peritoneal
dialysis patients, several factors are known to affect se-
rum albumin levels [6]. Multivariate analysis demon-
strated that low plasma albumin concentration correlates
most strongly with markers of inflammation and perito-
neal albumin loss [5, 7].
Elevated levels of plasma fibrinogen have also been
reported in predialysis [8] as well as in dialysis patients [9]
and have been associated with an increased prevalence
of coronary heart disease (CHD) both in the normal
situation [10] as well as in dialysis patients [11].
The mechanisms responsible for the hyperfibrinogen-
emia are not fully understood in dialysis patients. Fibrin-
ogen is an acute-phase protein and end-stage renal dis-
ease (ESRD) is associated with significant increases in
the acute phase [12]. One possibility is that fibrinogen
synthesis is increased as a component of the acute-phase
response [13]. Albumin synthesis and that of fibrinogen
are coordinately up-regulated in the presence of urinary
protein losses in nephrotic patients [14], suggesting a
second mechanism that may also be recruited in dialysis
patients in whom loss of albumin across the peritoneal
membrane may significantly reduce albumin concentra-
tion by a noninflammatory route.
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Table 1. Clinical data of the patients and control subjects
Age Weight Body surface Daily protein
Renal disease year Gender kg area m2 intake g/kg/day Medication
Predialysis patients (N  6)
1 Chronic pyelonephritis 59 M 82.6 2.0 0.9 1
2 Reflux nephropathy 49 M 72.6 1.9 1.1 1
3 Interstitial nephritis 51 M 85.7 2.1 0.8 —
4 IgA nephropathy 19 F 83.0 1.9 0.8 1
5 Unknown 56 F 74.4 1.9 0.9 —
6 Reflux nephropathy 52 F 70.4 1.8 0.7 2
MeanSEM 486a 3M/3F 78.12.6a 1.90.0a 0.80.0a
Peritoneal dialysis patients (N  7)
7 Glomerulonephritis 49 M 87.1 2.1 0.7 2
8 Unknown 54 M 78.3 1.9 1.1 1
9 Interstitial nephritis 54 F 69.3 1.8 1.0 1
10 Unknown 45 F 58.8 1.7 0.8 1
11 Polycystic disease 70 F 71.6 1.8 0.8 2
12 SLE nephritis 39 F 70.3 1.8 n.d. 1, 2, 3
13 Reflux nephropathy 53 F 68.1 1.7 0.8 2
MeanSEM 524a 2M/5F 71.93.3a 1.80.0a 0.90.0a
Control subjects (N  8)
MeanSEM 453 4M/4F 73.35.1 1.90.1 1.00.1 —
SLE is systemic lupus erythematosus; 1  angiotensin-converting enzyme (ACE) inhibitor, 2  -blocker, 3  anti-inflammatory medication (10 mg prednisone).
a Not significant
In this study, we tested the hypothesis whether albu-
min and fibrinogen synthesis are part of a coordinated
up-regulated hepatic response in patients with CRF (pre-
dialysis as well as patients on peritoneal dialysis) using
endogenous labeling with 13C-valine. Besides, several fac-
tors known to affect albumin and fibrinogen synthesis in
patients with CRF, including nutritional status, adequacy
of dialysis, state of inflammation, metabolic acidosis, in-
sulin resistance, and exogenous protein loss were studied.
METHODS
Subjects
Six predialysis patients (three males, three females),
seven peritoneal dialysis patients (two males, five fe-
males), and eight control subjects (four males and four
females) participated in the study. Two patients in the
predialysis group had reflux nephropathy, one patient
had interstitial nephritis, one patient had immunoglobu-
lin A (IgA) nephropathy, one patient had chronic pyelo-
nephritis, and the cause of renal disease in one patient
was unknown. The patients in the peritoneal dialysis
group had glomerulonephritis, interstitial nephritis, po-
lycystic kidney disease, reflux nephropathy, systemic lu-
pus erythematosus (SLE) nephritis, and the cause of renal
failure was unknown in two patients. Patients on perito-
neal dialysis treatment included those on continuous am-
bulatory peritoneal dialysis (CAPD) or CAPD in combi-
nation with automated peritoneal dialysis (APD). The
minimum time on dialysis was 9 months. Only one patient
was studied on two occasions (predialysis and on perito-
neal dialysis treatment (patients 6 and 13 in Table 1),
whereas two other patients from the predialysis group
(patients 1 and 2) dropped out (transplantation or died).
The other patients had not yet started on peritoneal
dialysis. Patients with type 2 diabetes and/or other under-
lying cardiovascular diseases and patients with volume
overload were excluded from the study. The clinical data
from the patients and control subjects are shown in Table 1.
Only patient 12 was receiving anti-inflammatory medica-
tion (10 mg prednisone). Specific medication other than
vitamins, erythropoietin, iron supplementation, sodium
bicarbonate, and phosphate binder supplementation are
presented in Table 1. Patient 8 smoked cigarettes. Before
isotope infusion, the patients recorded their food intake
for 3 days and collected 24-hour urine for 3 consecutive
days. Additionally, the peritoneal dialysis group also col-
lected 24-hour dialysis fluid for 3 days.
Control studies were done in eight healthy subjects
(four males, four females). Control subjects also recorded
their food intake for 3 days and collected one 24-hour
urine sample. Urine was analyzed for urea, creatinine, pro-
tein, albumin, and fibrinogen. Dialysis fluid was analyzed
for urea, protein, albumin, and fibrinogen. All patients
and volunteers agreed to participate after signing an
informed consent form, in accordance with the Helsinki
Declaration of Human Rights. The Institutional Ethical
Committee for Studies in Humans approved this study.
Infusion protocol
The subjects came to the research unit in the morning
after a 10-hour fast. Before the start of the infusion,
subjects were weighed and two intravenously cannulas
were placed for blood sampling and infusion of the la-
beled valine. No food was given during the tracer infu-
sion and the subjects were only allowed to drink water.
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The last bag of peritoneal dialysate was drained for a
minimum of 6 hours prior to the start of tracer infusion.
During the infusion period, no dialysis was performed.
At baseline (t  0), predialysis patients received a
priming dose of 11.5 mol/kg l-[1-13C]-valine (isotope
mole fraction 0.99) (Mass Trace, Woburn, MA, USA)
intravenously in 2 minutes, followed by a continuous
infusion of 11.5 mol/kg/hour l-[1-13C]-valine for 10
hours. The priming dose for patients on peritoneal dial-
ysis was 8 mol/kg and 15 mol/kg for control subjects,
followed by a continuous infusion 8 mol/kg/hour and
15 mol/kg/hour for 10 hours. Blood samples were taken
in heparin-containing and citrate-containing tubes from
the contralateral arm at t  0, 30, 60, 180, 300, 360, 420,
480, 540, and 600 minutes. Samples were kept on ice
until plasma was separated by centrifugation (15, 3000
rpm at 4C).
Preinfusion measurements
Plasma albumin, plasma fibrinogen, total protein, bi-
carbonate, creatinine, glucose, urea in urine, creatinine
in urine, and protein in urine were measured with stan-
dard laboratory methods on a Vitros 950 (Johnson & John-
son, Clinical Diagnostics, NY, USA). The measurement of
albumin was based on the bromcresol green method.
C-reactive protein (CRP) was measured using a high-
sensitivity CRP immunonephelometric assay (detection
limit 0.175 mg/L) (Dade Behring, Marburg, Germany).
Insulin was measured with a competitive radioimmuno-
assay using a polyclonal antiinsulin antibody (Caris 46),
125I-Insulin (IM166) (Amersham Biosciences, Roosendaal,
The Netherlands), as a tracer and Humuline (YV2632)
(AMV Lilly, Indianapolis, IN, USA) as a standard. Albu-
min in urine and dialysis fluid was measured on a Linx 30
analyzer (Konelab; Thermo Clinical Labsystems, Espoo,
Finland). Determination of fibrinogen in urine and dialysis
fluid was done using rocket electrophoresis. The amino
acid profile was determined using a Biochrom 20 amino
acid analyzer (Pharmacia Biotech, Ltd., Cambridge, En-
gland).
Isolation of albumin and ketoisovaleric acid (KIV)
The isolation of albumin from heparinized plasma is
based on differential solubility in absolute ethanol from
trichloroacetic acid (TCA)-precipitated proteins and was
performed as described in detail previously [14]. The prep-
aration of KIV prior to measurement was performed ac-
cording to the method of Rocchiccioli, Leroux, and Car-
tier [15] with some slight modifications. The modified
method has been described in detail elsewhere [16].
Isolation of fibrinogen
Fibrinogen was purified from plasma anticoagulated
with citrate based on the method of Vila et al [17]. Briefly,
0.5 mL plasma was added very slowly to 0.5 mL 80 g/L
polyethylene glycol 6000 (Merck, Darmstadt, Germany).
The mixture was placed on ice and gently shaken for 10
minutes. After centrifugation (10 minutes, 2500 rpm at
4C) the precipitate was redissolved in 1 mL phosphate
buffer (0.01 mol/L Na2HPO4 and 0.15 mol/L NaCl, pH 7.4)
and subsequently precipitated with 0.5 mL 2 mol/L acetic
acid acetate buffer (pH 4.6). This mixture was again placed
on ice for 30 minutes and gently shaken. After centrifuga-
tion the precipitate was redissolved in 1 mL phosphate
buffer (0.036 mol/L Na2HPO4, pH 7.8) and precipitated
with 330 L 4 mol/L (NH4)2SO4. After centrifugation,
the pellet was redissolved in 1 mL phosphate buffer
(0.018 mol/L Na2HPO4, pH 7.8). A part of the isolated
fibrinogen was used to monitor purity and identification.
Subsequently, an aliquot of the solution containing 500
g fibrinogen was precipitated by adding 1 mL ice-cold
2 mol/L HClO4 in order to remove the free amino acids.
Hydrolysis of fibrinogen was done in 0.5 mL 6 mol/L HCl
[18], followed by cation exchange chromatography (AG
50W-X8) (Bio-Rad Laboratories, Hercules, CA, USA)
and dried under N2. Derivatization was done according to
the method of Husek [19].
Fibrinogen rocket electrophoresis
Fibrinogen rocket electrophoresis was used to assess
loss of fibrinogen in urine and dialysis fluid in the studied
patients. A fibrinogen calibration curve (standard  2.5
mg/mL) (Dade Behring) was made in physiologic salt
ranging from 16 to 250 mg/L to detect loss of fibrinogen
in urine. One milliliter of urine of the patients was freeze-
dried and dissolved in 100 L physiologic salt. A 2 L
sample was loaded on a gel containing 1% agarose M
(Amersham Pharmacia Biotech, Uppsala, Sweden) con-
taining 15 L polyclonal antihuman fibrinogen antibody
(Dade Behring). Electrophoresis was done for 16 hours
at 200 V and 10 mA per gel using Tris-Tricine, pH 8.6,
as electrophoresis buffer, after which the gel was washed
for a minimal 6 hours in physiologic salt. After washing,
the gel was dried and detection of the samples was done
with 0.25% Coomassie staining. Quantitative results are
obtained by measuring the distance from the origin to
the tip of the peak. The peak height was proportional
to the concentration. A spiked urine sample was used
as positive control and urine of different control subjects
were used as negative controls.
To detect fibrinogen loss in dialysis fluid, a fibrinogen
calibration curve was made in physiologic salt ranging
from 16 to 250 mg/L. One milliliter dialysis fluid was
freeze-dried and dissolved in 100 L and 200 L physio-
logic salt. Samples were run following the same proce-
dure as described above. Unused dialysis fluid and physi-
ologic salt were used as negative controls and a spiked
dialysis sample was used as a positive control. The intra-
variation of the rocket electrophoresis was 2.6% and the
intervariation was 5.3%.
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Fig. 1. Model for estimation of albumin and fibrinogen fractional syn-
thesis rates (FSR) for patients and control subjects. Compartment 1
represents the precursor pool and compartment 2 represents the plasma
albumin or fibrinogen pool. The k-value represents the rate constant.
The equation used for calculation of FSR_day  k (2,1)  24  100;
24 is the conversion of pools/hour to pools/day; 100 is the conversion
of pools to %.
Derivatives and mass spectrometric measurements
The preparation of N(O,S) methoxycarbonylmethyl-
ester derivatives of albumin and fibrinogen and the deri-
vatization of KIV with MTBSTFA:pyridine (3:1) and
mass spectrometric measurements were described in de-
tail elsewhere [16, 20].
Kinetic analysis
Fractional synthesis rates (FSR) for albumin and fi-
brinogen were calculated from the tracer/tracee data and
the data were fitted using the SAAM II software (Simula-
tion Analysis and Modeling, Seattle, WA, USA). The abso-
lute synthesis rate (ASR), which is the amount of protein
synthesized per day, was calculated as the product of the
FSR and the plasma pool (plasma volume  plasma
concentration). To adjust for different body weights, the
quantities are expressed per kilogram body weight. Plasma
volumes in all subjects were calculated from body surface
area (BSA) using the formulas described by Hurley [21].
Calculation of the FSR for albumin and fibrinogen
was done using a two-compartment model (Fig. 1), where
compartment 1 is the precursor pool and compartment
2 represents the protein pool. The delay was approxi-
mately 30 minutes for albumin as well as fibrinogen. The
equation used for calculation of the FSR/day (%/day) 
k(2,1) 24 100. Since steady state is achieved, subtrac-
tion of external loss from the ASR results in the absolute
catabolic rate (ACR) and presumes that all direct losses
of albumin are measured. The fractional catabolic rate
(FCR) was calculated by dividing the ACR by the plasma
pool size.
Statistical analysis
Data are expressed as mean SEM. One-way analysis
of variance (ANOVA) assessed the significance of differ-
ences and multiple comparisons was done using Bonfer-
roni t test. If normality test or equal variance test failed,
a Kruskal-Wallis one-way ANOVA on ranks was per-
formed and multiple comparisons was done using Dunn’s
test. Correlations were performed by linear regression
analysis. A P value 0.05 was considered to be statisti-
cally significant.
RESULTS
Baseline data
The plasma values of total protein, albumin, fibrino-
gen, CRP, insulin, and bicarbonate are shown in Table
2. Plasma albumin is significantly lower in peritoneal
dialysis patients than in control subjects (33.0  0.9 g/L
versus 36.2  0.5 g/L, P  0.05). In contrast to albumin,
plasma fibrinogen concentration was significantly greater
both in predialysis patients (4.8  0.3 g/L, P  0.01) and
peritoneal dialysis patients (5.2  0.4 g/L compared to
control 3.0 0.2 g/L, P 0.001). While fibrinogen levels
tended to be greater in patients who were treated with
peritoneal dialysis when compared to those who had not
yet begun treatment (4.8  0.3 g/L versus 5.2  0.4 g/L),
these differences did not achieve significance. Plasma
bicarbonate was not significantly lower in predialysis pa-
tients compared to peritoneal dialysis patients and con-
trol subjects (21.6 2.3 mmol/L versus 26.1 1.5 mmol/L
versus 24.0  1.0 mmol/L). No significant difference is
found for total protein, CRP, and plasma volume in
the three groups (predialysis versus peritoneal dialysis
versus control subjects).
Protein losses in urine and dialysis fluid are shown in
Table 3. The reported value is the mean of 3 days urine
collection and dialysis fluid collection in the patient
groups. Proteinuria and albuminuria was constant over
the 3 days as also found for protein loss, albumin loss,
and fibrinogen loss in dialysis fluid. Mean urinary protein
losses in predialysis patients was 3.9  1.0 g/day (range,
1.4 to 7.2 g/day) and 0.8  0.2 g/day (range, 0.3 to 1.5
g/day) for dialysis patients and was significantly greater
in both groups compared to control subjects (3.9  1.0
g/day, P 0.01; and 0.8 0.2 g/day versus control subjects
0.1 0.0 g/day, P 0.01). Urinary protein loss was also
significant different between predialysis and peritoneal
dialysis patients (3.9  1.0 g/day versus 0.8  0.2 g/day,
P  0.05). The urinary loss of albumin was significantly
greater in both patient groups compared to control sub-
jects (predialysis patients, albumin 24  6 mg/kg/day
versus 0.1  0.0 mg/kg/day, P  0.001; and patients
on peritoneal dialysis, albumin 4  1 mg/kg/day versus
0.1  0.0 mg/kg/day, P  0.001).
Albuminuria in predialysis patients was significantly
greater compared to patients on peritoneal dialysis (24
6 mg/kg/day versus 4  1 mg/kg/day, P  0.01). Mean
protein loss in dialysis fluid was 6.2  0.9 g/day (range,
3.3 to 9.9 g/day). The mean loss of albumin in dialysis
fluid was 52  5 mg/kg/day (range, 30 to 67 mg/kg/day)
and 0.7  0.2 mg/kg/day for fibrinogen (range, 0.2 to
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Table 2. Biochemical parameters in plasma from chronic renal failure (CRF) patients and control subjects
C-reactive [HCO	3 ] Plasma
Total protein Albumin Fibrinogen protein Insulin bicarbonate volume
g/L g/L g/L lg/mL mE/L HOMA-R mmol/L mL/kg
Predialysis patients (N  6)
1 80.2 40.1 6.6 10.8 16 4.0 22.0 38
2 80.1 40.0 4.9 3.6 30 9.1 25.9 40
3 64.4 35.6 4.0 3.4 18 4.2 19.3 38
4 60.4 30.1 4.7 3.7 26 5.0 12.4 33
5 80.0 42.5 4.4 1.7 7 1.6 28.3 36
6 76.0 38.4 4.2 1.4 20 4.9 21.4 35
MeanSEM 74.23.3d 37.81.8d 4.80.3b 4.11.4d 19.53.3c 5.10.9b 21.62.3d 371d
Peritoneal dialysis patients (N  7)
7 59.3 28.7 4.5 1.0 5 1.2 25.0 38
8 71.3 36.1 6.6 8.6 12 3.1 22.0 39
9 65.8 33.2 4.6 0.6 15 3.4 33.8 37
10 73.7 35.0 4.1 6.4 9 2.1 23.8 40
11 65.2 35.0 7.1 9.4 13 3.4 24.2 35
12 65.0 31.8 5.1 2.9 31 7.4 24.7 37
13 65.1 31.7 5.0 8.9 13 3.7 29.4 36
MeanSEM 66.41.7d 33.00.9a 5.20.4c 5.41.4d 14.03.1b 3.41.7a 26.11.5d 371d
Control subjects (N  8)
MeanSEM 67.41.5 36.20.5 3.00.2 3.21.3 5.00.0 1.50.9 24.01.0 391
aP  0.05, compared to control subjects; bP  0.01, compared to control subjects; cP  0.001, compared to control subjects; dNot significant
Table 3. Biochemical parameters in urine and dialysis fluid from patients and control subjects
Urinary loss Dialysis fluid
Protein Albumin Protein Albumin Fibrinogen Creatinine clearance
g/day mg/kg/day g/day mg/kg/day mg/kg/day mL/min/1.73 m2 Kt/V
Predialysis patients (N  6)
1 7.0 33 — — — 8 —
2 2.6 20 — — — 7 —
3 1.4 6 — — — 11 —
4 7.2 50 — — — 9 —
5 3.5 23 — — — 9 —
6 1.8 11 — — — 5 —
MeanSEM 3.91.0a 246b — — — 81a —
Peritoneal dialysis patients (N  7)
7 1.5 8 9.9 67 1.8 — 1.70
8 1.5 6 7.9 63 0.3 — 2.55
9 0.3 1 4.5 50 0.3 — 1.90
10 0.3 1 4.6 49 0.5 — 1.70
11 0.7 1 7.5 64 1.1 — 1.99
12 0.8 1 3.3 30 0.2 — 1.70
13 0.8 9 5.6 40 0.8 — 2.19
MeanSEM 0.80.2a,c 41b,d 6.20.9 525 0.70.2 — 1.960.12
Control subjects (N  8)
MeanSEM 0.10.0 0.10.0 — — — 9712 —
aP 0.01, compared to control subjects; bP 0.001 compared to control subjects; cP 0.05, compared to predialysis subjects; dP 0.01, compared to predialysis patients
1.8 mg/kg/day). Mean total protein loss in patients on
peritoneal dialysis was 7.0 1.0 g/day (range, 4.1 to 11.4
g/day) or 95 11 mg/kg/day (range, 58 to 131 mg/kg/day).
Mean total albumin loss was 4.1  0.6 g/day (range, 2.1
to 6.6 g/day) or 56  5 mg/kg/day (range, 31 to 75 mg/kg/
day). In predialysis patients, albumin loss was 45%  4%
(range, 27% to 57%) of total protein loss and 61%  4%
(range, 52% to 73%) for patients on peritoneal dialysis.
Creatinine clearance calculated, using the Cockcroft-
Gault formula, was significantly decreased in predialysis
patients compared to control subjects (8  1 mL/min/
1.73 m2 versus 97  12 mL/min/1.73 m2, P  0.01). The
mean Kt/V value in the peritoneal dialysis group, where
V was estimated by the formula of Watson and Watson,
was 1.96  0.12 (range, 1.70 to 2.55).
Synthesis rate of albumin in patients with CRF and in
control subjects
Albumin kinetics in predialysis patients and patients
on peritoneal dialysis are shown in Table 4. The ASR
of albumin tended to be greater in both patient groups
compared to control subjects (110  11 mg/kg/day and
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Table 4. Kinetics of albumin and fibrinogen
FSR albumin FSR fibrinogen ASR albumin ASR fibrinogen FCR albumin FCR fibrinogen
%/day %/day mg/kg/day mg/kg/day %/day %/day
Predialysis patients (N  6)
1 8.6 24.6 129 61 6.4 24.6
2 9.7 21.6 157 43 8.5 21.6
3 7.4 18.2 100 28 6.9 18.2
4 8.9 18.1 88 28 3.8 18.1
5 6.3 16.9 95 26 4.7 16.9
6 6.6 15.8 88 23 5.7 15.8
MeanSEM 7.90.6d 19.21.3d 11011d 356d 6.00.7d 19.21.3d
Peritoneal dialysis patients (N  7)
7 10.0 23.7 108 40 3.0 22.6
8 11.9 22.0 166 56 7.0 21.9
9 7.7 18.1 94 31 3.5 18.0
10 8.3 27.9 116 45 4.8 27.6
11 11.6 21.6 144 54 6.4 21.1
12 9.5 17.6 123 36 4.5 17.5
13 11.1 29.9 126 53 6.8 29.4
MeanSEM 10.00.6b,c 23.01.7d 1259a 454b 5.10.6d 22.61.7d
Control subjects (N  8)
MeanSEM 6.70.6 24.61.6 939 293 6.70.6 24.61.6
Abbreviations are: ASR, absolute synthesis rate; FSR, fractional synthesis rate.
aP  0.05 compared to control subjects; bP  0.01 compared to control subjects; cP  0.05 compared to predialysis subjects; d not significant
125  9 mg/kg/day versus 93  9 mg/kg/day) and was
significantly greater in peritoneal dialysis patients. The
FSR of albumin also tended to be greater in both patient
groups compared to control subjects (7.9  0.6%/day
and 10.0  0.6%/day versus 6.7  0.6%/day, P  0.01),
but was only significantly greater in peritoneal dialysis
patients. Albumin FSR was also significantly higher in
patients on peritoneal dialysis compared to predialysis
patients (7.9 0.6%/day and 10.0 0.6%/day, P 0.05).
No significant difference was found for albumin FCR in
both patient groups compared to control subjects.
Synthesis rate of fibrinogen in patients with CRF and
in control subjects
Fibrinogen kinetics in patients with CRF and control
subjects are shown in Table 4. Fibrinogen ASR is signifi-
cantly higher in the peritoneal dialysis group compared
to control subjects (45  4 mg/kg/day versus 29  3
mg/kg/day, P  0.01) and tends to be increased in the
predialysis group (35  6 mg/kg/day versus 29  4 mg/
kg/day).
No significant difference was found for fibrinogen FSR
in patients and control subjects (Table 4).
Correlations
Considering the data in control subjects and patients
together, several parameters were tested. Albumin syn-
thesis strongly correlated with fibrinogen synthesis (r 2 
0.665, P  0.0001, N  21) (Fig. 2) but not with plasma
albumin concentration (r 2  0.003, N  21). Plasma
fibrinogen strongly correlated with the ASR of fibrino-
gen (r 2 0.643, P 0.0001, N 21) and ASR of albumin
(r 2 0.498, P 0.001, N 21). No significant correlation
Fig. 2. Relationship between absolute synthesis rate (ASR) of fibrino-
gen (mg/kg/day) and the ASR of albumin (mg/kg/day) for predialysis
patients (N  6) (), peritoneal dialysis patients (N  7) (), and
control subjects (N  8) (). The 95% confidence limits of the entire
group are shown on either side of the regression line (r 2  0.665, P 
0.0001, N  21).
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was found for plasma insulin and albumin synthesis (r 2 
0.126, P  0.11, N  21).
In the control group, albumin synthesis correlated with
fibrinogen synthesis (r 2  0.527, P  0.05, N  8). No
significant correlation was found for albumin synthesis
and CRP (r 2  0.201, P  0.31, N  8) or fibrinogen
synthesis and CRP (r 2  0.165, P  0.36, N  8).
In the patient groups, albumin synthesis correlated
with fibrinogen synthesis (r 2  0.636, P  0.01, N  13).
Plasma fibrinogen also strongly correlated with the ASR
of fibrinogen (r 2  0.614, P  0.01, N  13) and the
ASR of albumin (r 2  0.636, P  0.01, N  13). Total
albumin loss strongly correlated with total protein loss
(r 2  0.930, P 0.0001, N 13). Total albumin loss (r2 
0.338, P 0.037, N 13), but not total protein loss (r 2 
0.250, P 0.08, N 13) correlated with plasma albumin
concentration. Albumin ASR did not correlate with total
albumin loss (r2  0.09, N 13) or total protein loss (r 2 
0.140, N  13). Furthermore, no correlation was found
for albuminuria (r 2  0.001, N  13), proteinuria (r 2 
0.03, N 13) and plasma fibrinogen concentration. Albu-
min synthesis did not correlate with plasma insulin (r 2 
0.006, P  0.80).
DISCUSSION
In the present study, using stable isotopes, we showed
that both albumin synthesis and fibrinogen synthesis
were increased in patients with CRF. A strong correla-
tion was found between the synthesis rates of both liver
derived proteins in patients and control subjects (r 2 
0.665, P  0.0001, N  21) as well as in both groups
separately (r 2  0.636, P  0.01, N  13 and r 2  0.527,
P  0.05, N  8), suggesting a tightly coordinated up-
regulated process. This finding is also observed in ne-
phrotic patients and in hemodialysis patients, suggesting
a common mechanism may be acting in these divergent
patient groups [13, 22].
In our patient group, a correlation was found between
total albumin loss and plasma albumin (r 2  0.338, P 
0.05, N  13), suggesting that albumin loss is a major
determinant for plasma albumin levels as also reported
by others [5, 7, 23]. The increased rate of albumin synthe-
sis in these patients off sets the albumin loss and is likely
to be regulated in a manner to defend plasma albumin
concentration. In the predialysis group, the small in-
crease in albumin synthesis (20%) is sufficient to com-
pensate urinary albumin loss, resulting in normal plasma
albumin concentrations. In peritoneal dialysis patients,
however, albumin synthesis is significantly greater than
in control subjects (35%), while plasma albumin concen-
tration is not normalized, suggesting inability to increase
albumin synthesis rate to higher levels or the existence
of other defense mechanisms. In this study, plasma vol-
ume was calculated from BSA and was not estimated
with the Evans Blue method as recently described in
our group for nephrotic patients [14]. Due to the toxic
properties of the dye Evans Blue, as stated in the guide-
lines for controlling safety hazards in hospitals, the Ethi-
cal Committee of our hospital did not give their consent
for such experiment. Since it has been reported that
plasma volume is usually increased in patients with CRF
[23, 24], we chose to calculate the data based on normal
plasma volume. This results in underestimation than
overestimation of the reported data.
Fibrinogen synthesis was increased in the peritoneal
dialysis group. We hypothesize that fibrinogen synthesis
is increased as part of a coordinated response of liver
derived proteins such as occurs in the nephrotic syn-
drome. Of 13 patients, 11 were prescribed medication,
consisting of a -blocker, an angiotensin-converting en-
zyme (ACE) inhibitor, or a combination of both drugs.
Both drugs are known to reduce plasma fibrinogen levels
[25, 26], yet fibrinogen levels remained significantly ele-
vated. In contrast to albumin, fibrinogen is lost in perito-
neal dialysis fluid, but not in urine as observed in our
patients and also increases in plasma despite the losses.
Despite the fibrinogen loss, fibrinogen FCR is normal,
suggesting that the increase in plasma fibrinogen concen-
tration results from increased synthesis rate alone as
also found in patients with the nephrotic syndrome for
fibrinogen [14], lipoprotein(a) [Lp(a)] [27] and 
2-macro-
globulin [28].
Several factors may affect albumin and fibrinogen me-
tabolism in patients with CRF, including nutritional status,
adequacy of dialysis, state of inflammation, metabolic aci-
dosis, insulin resistance, and exogenous protein loss [5, 7].
Malnutrition has been reported to be a potential cause
of hypoalbuminemia in patients with CRF [29], since a
low protein intake decreases albumin synthesis [30]. In
this report, albumin ASR in three of six predialysis pa-
tients and in six of seven peritoneal dialysis patients
was higher than mean albumin ASR in control subjects.
Furthermore, daily protein intake in all the patients stud-
ied was close to normal and dialysis adequacy was suffi-
cient (mean Kt/V  1.96  0.12, N  7), suggesting that
the hypoalbuminemia in peritoneal dialysis group is not
explained by malnutrition or inadequate dialysis.
It had recently been recognized that inflammation
rather than protein malnutrition plays a role in albumin
synthesis in patients on hemodialysis [31]. In contrast to
other studies of both predialysis patients [12] and those
with ESRD [7, 32], our patients had CRP values that
approached the normal range. Indeed, there was no sig-
nificant difference among these groups. However, plasma
CRP in one control subject was 10 mg/L. Exclusion of
this subject results in a mean plasma CRP value of 2.1 
0.9 mg/L that is in agreement with values reported for
healthy controls [33]. No significant differences were ob-
served after recalculation of the data, suggesting that it
is unlikely that inflammation has contributed substan-
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tively to either albumin levels or fibrinogen levels in this
group of patients.
Metabolic acidosis has been recognized as an impor-
tant stimulus for protein catabolism and could also con-
tribute to hypoalbuminemia. In normal individuals, albu-
min synthesis was reduced during metabolic acidosis [34].
Since plasma bicarbonate is not different in control sub-
jects and patients, despite an increased albumin synthesis
rate in the latter group, these data suggest that corrected
metabolic acidosis is of minor importance for hypo-
albuminemia in patients with CRF [35]. In one patient
(patient 4, predialysis group), plasma bicarbonate was
12.4 mmol/L and this patient had the lowest serum albu-
min concentration (30.1 g/L) and lowest synthesis rate
(88 mg/kg/day), suggesting that metabolic acidosis may
have contributed to hypoalbuminemia is this patient.
However, no correlation was found between plasma bi-
carbonate and plasma albumin (r 2  0.01, P  0.70), as
reported by others [29].
Several studies clearly showed that the action of insu-
lin is markedly impaired in patients with CRF [36, 37]
and exogenous insulin administration increases albumin
synthesis in humans [38]. The reduced action of insulin
to increase albumin synthesis could therefore be of rele-
vance. Plasma insulin levels and homeostasis model as-
sessment of insulin resistance (HOMA-R) index, but not
albumin synthesis, tended to be higher in predialysis
patients compared to patients on dialysis. This might
suggest a higher degree of insulin insensitivity in the
predialysis group, implying that intensive glucose loading
during peritoneal dialysis has no or little effect on insulin
resistance. Additionally, no significant correlation was
found for plasma insulin and albumin synthesis rate in
the whole group (r 2  0.126, P  0.11, N  21) or in
the patient group (r 2  0.006, P  0.80). It is important
to notice that, despite absence of direct evidence for
either of these factors, the occurrence of an indirect
effect of these factors cannot completely excluded.
The present data demonstrate that albumin synthesis
is 20% higher in predialysis patients and 35% higher in
peritoneal dialysis patients. Renal failure per se does
not reduce albumin synthetic rate [39]. In hemodialysis
patients, the increase in albumin synthesis rate is similar
as observed in our patients, suggesting no effect of dial-
ysis modality on albumin synthesis [22, 29]. In the ne-
phrotic syndrome, however, the increase in albumin syn-
thesis rate described previously was much higher (100%)
[14], compared to patients on peritoneal dialysis, despite
similar amount of external protein loss in both patient
groups. This phenomenon might be explained by lower
net amino acid availability in dialysis patients [40, 41].
Alternatively, serum albumin concentration was signifi-
cantly less in the nephrotic patients, perhaps providing
a greater stimulus for albumin synthesis in that group.
Patients with CRF have reduced plasma levels of
branched-chain amino acids and keto analogs [42–44] in
contrast to nephrotic patients, where only the keto acid
pool is reduced [43]. In order to increase these pools,
oral supplementation with amino acids or keto acids,
intravenous administration of amino acids or addition
of amino acids to dialysis fluid could be useful. Amino
acid and keto acid supplementation increases albumin
synthesis in rats [44, 45]. In humans, supplementation of a
combination of amino acids and keto analogs of essential
amino acids to patients with CRF, resulted in an increase
in plasma albumin and plasma transferrin concentration
[46–48]. Unfortunately, plasma fibrinogen concentration
was not measured. In peritoneal dialysis, supplementa-
tion of amino acids in dialysis fluid is possible. Recently,
we studied albumin kinetics in two patients (patients 9
and 10) using an experimental 1% glycerol amino acid
dialysis fluid during 4 weeks, but no effect on plasma
albumin concentration was found (31.7 g/L and 35.1 g/L).
In one patient (patient 9), no change of albumin synthesis
was found (93 mg/kg/day), whereas the other patient
(patient 10) showed an increase in albumin synthesis
rate (148 mg/kg/day), despite similar concentrations of
branched-chain amino acids in both patients before and
after dialysis with the experimental 1% glycerol amino
acid dialysis fluid (Baxter, Utrecht, The Netherlands)
(140 and 109 mol/L valine, 65 and 56 mol/L leucine,
and 34 and 29 mol/L isoleucine, respectively). Further-
more, in two other studies a marginal effect of amino acid
supplementation via the peritoneum on plasma albumin
and transferrin levels was found [49, 50]. This suggests
that amino acid supplementation is likely not useful for
peritoneal dialysis patients with a protein intake that is
close to normal.
CONCLUSION
Albumin and fibrinogen synthesis are coordinately up-
regulated in CRF. In peritoneal dialysis patients both
albumin and fibrinogen are lost in dialysis fluid. Albumin
synthesis is up-regulated, but the response is insufficient
to maintain a normal albumin concentration in dialysis
patients. In contrast, patients with near-ESRD are capable
of increasing albumin synthetic rate sufficiently to main-
tain a normal albumin concentration despite significant
urinary losses. In this study, the observed hypoalbumin-
emia in peritoneal dialysis patients is not explained by
malnutrition, inadequate dialysis, inflammation, meta-
bolic acidosis, or insulin resistance, speculating that peri-
toneal albumin loss is of relevance. Since fibrinogen syn-
thesis is positively correlated with plasma fibrinogen
concentration, this linkage may contribute to the risk of
cardiovascular disease in patients with renal failure.
ACKNOWLEDGMENTS
The authors thank Coby Slee for her assistance during the infusions
and Nel Willekens for her assistance using the fibrinogen rocket electro-
phoresis. Further, the authors thank the LC-group of the Department
of Metabolic Diseases for measurement of the amino acid profiles.
The Dutch Kidney Foundation supported this work (C98.1777).
Prinsen et al: Albumin and fibrinogen kinetics in CRF 1503
Reprints requests to Berthil H.C.M.T. Prinsen, University Medical
Center Utrecht, Department of Vascular Medicine and Metabolism, HP
G02.402, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
E-mail: B.Prinsen@azu.nl
REFERENCES
1. Mittman N, Avram MM, Oo KK, et al: Serum prealbumin predicts
survival in hemodialysis and peritoneal dialysis: 10 years of pro-
spective observation. Am J Kidney Dis 38:1358–1364, 2001
2. Collins AJ, Li S, Ma JZ, et al: Cardiovascular disease in end-
stage renal disease patients. Am J Kidney Dis 38:S26–S29, 2001
3. Keshaviah P, Collins AJ, Ma JZ, et al: Survival comparison
between hemodialysis and peritoneal dialysis based on matched
doses of delivered therapy. J Am Soc Nephrol 13(Suppl 1):S48–S52,
2002
4. Avram MM, Goldwasser P, Erroa M, et al: Predictors of survival
in continuous ambulatory peritoneal dialysis patients: The impor-
tance of prealbumin and other nutritional and metabolic markers.
Am J Kidney Dis 23:91–98, 1994
5. Yeun JY, Kaysen GA: Factors influencing serum albumin in dial-
ysis patients. Am J Kidney Dis 32:S118–S125, 1998
6. Mitch WE: Insights into the abnormalities of chronic renal disease
attributed to malnutrition. J Am Soc Nephrol 13(Suppl 1):S22–S27,
2002
7. Yeun JY, Kaysen GA: Acute phase proteins and peritoneal dialy-
sate albumin loss are the main determinants of serum albumin in
peritoneal dialysis patients. Am J Kidney Dis 30:923–927, 1997
8. Jungers P, Massy ZA, Khoa TN, et al: Incidence and risk factors
of atherosclerotic cardiovascular accidents in predialysis chronic
renal failure patients: A prospective study. Nephrol Dial Transplant
12:2597–2602, 1997
9. Irish A: Cardiovascular disease, fibrinogen and the acute phase
response: Associations with lipids and blood pressure in patients
with chronic renal disease. Atherosclerosis 137:133–139, 1998
10. Heinrich J, Balleisen L, Schulte H, et al: Fibrinogen and factor
VII in the prediction of coronary risk. Results from the PROCAM
study in healthy men. Arterioscler Thromb 14:54–59, 1994
11. Koch M, Kutkuhn B, Trenkwalder E, et al: Apolipoprotein B,
fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes
predict coronary artery disease in hemodialysis patients. J Am Soc
Nephrol 8:1889–1898, 1997
12. Stenvinkel P, Heimburger O, Paultre F, et al: Strong association
between malnutrition, inflammation, and atherosclerosis in chronic
renal failure. Kidney Int 55:1899–1911, 1999
13. Kaysen GA, Dubin JA, Muller HG: The impact of albumin
synthesis rate and the acute phase response in the dual regulation
of fibrinogen levels in hemodialysis patients. Kidney Int 63:315–322,
2002
14. de Sain-van der Velden MG, Kaysen GA, de Meer K, et al:
Proportionate increase of fibrinogen and albumin synthesis in ne-
phrotic patients: Measurements with stable isotopes. Kidney Int
53:181–188, 1998
15. Rocchiccioli F, Leroux JP, Cartier P: Quantitation of 2-ketoacids
in biological fluids by gas chromatography chemical ionization mass
spectrometry of O-trimethylsilyl-quinoxalinol derivatives. Biomed
Mass Spectrom 8:160–164, 1981
16. Prinsen BH, de Sain-van der Velden MG, Kaysen GA, et al:
Transferrin synthesis is increased in nephrotic patients insuffi-
ciently to replace urinary losses. J Am Soc Nephrol 12:1017–1025,
2001
17. Vila V, Reganon E, Llopis F, et al: A rapid method for isolation of
fibrinogen from human plasma by precipitation with polyethylene
glycol 6,000. Thromb Res 39:651–656, 1985
18. Hill RL: Hydrolysis of proteins. Adv Protein Chem 20:37–107,
1965
19. Husek P: Amino acid derivatization and analysis in five minutes.
FEBS Lett 280:354–356, 1991
20. de Sain-van der Velden MG, Kaysen GA, Barrett HA, et al:
Increased VLDL in nephrotic patients results from a decreased
catabolism while increased LDL results from increased synthesis.
Kidney Int 53:994–1001, 1998
21. Hurley PJ: Red cell and plasma volumes in normal adults. J Nucl
Med 16:46–52, 1975
22. Giordano M, De Feo P, Lucidi P, et al: Increased albumin and
fibrinogen synthesis in hemodialysis patients with normal nutri-
tional status. J Am Soc Nephrol 12:349–354, 2001
23. Kaysen GA, Schoenfeld PY: Albumin homeostasis in patients
undergoing continuous ambulatory peritoneal dialysis. Kidney Int
25:107–114, 1984
24. Savdie E, Gibson JC, Crawford GA, et al: Impaired plasma tri-
glyceride clearance as a feature of both uremic and posttransplant
triglyceridemia. Kidney Int 18:774–782, 1980
25. Makris TK, Stavroulakis GA, Krespi PG, et al: Fibrinolytic/
hemostatic variables in arterial hypertension: Response to treat-
ment with irbesartan or atenolol. Am J Hypertens 13:783–788, 2000
26. Bhatia J, Mahajan P, Sikka M, et al: Effect of various antihyper-
tensive drugs on plasma fibrinogen levels in patients with essential
hypertension. Indian J Med Sci 55:491–494, 2001
27. de Sain-van der Velden MG, Reijngoud DJ, Kaysen GA, et al:
Evidence for increased synthesis of lipoprotein(a) in the nephrotic
syndrome. J Am Soc Nephrol 9:1474–1481, 1998
28. de Sain-van der Velden MG, Rabelink TJ, Reijngoud DJ, et al:
Plasma alpha 2 macroglobulin is increased in nephrotic patients
as a result of increased synthesis alone. Kidney Int 54:530–535, 1998
29. Kaysen GA, Rathore V, Shearer GC, et al: Mechanisms of hypo-
albuminemia in hemodialysis patients. Kidney Int 48:510–516, 1995
30. Kirsch R, Frith L, Black E, et al: Regulation of albumin synthesis
and catabolism by alteration of dietary protein. Nature 217:578–
579, 1968
31. Kaysen GA, Stevenson FT, Depner TA: Determinants of albumin
concentration in hemodialysis patients. Am J Kidney Dis 29:658–
668, 1997
32. Kaysen GA, Chertow GM, Adhikarla R, et al: Inflammation
and dietary protein intake exert competing effects on serum albu-
min and creatinine in hemodialysis patients. Kidney Int 60:333–340,
2001
33. Haidari M, Javadi E, Sadeghi B, et al: Evaluation of C-reactive
protein, a sensitive marker of inflammation, as a risk factor for
stable coronary artery disease. Clin Biochem 34:309–315, 2001
34. Ballmer PE, McNurlan MA, Hulter HN, et al: Chronic meta-
bolic acidosis decreases albumin synthesis and induces negative
nitrogen balance in humans. J Clin Invest 95:39–45, 1995
35. Brady JP, Hasbargen JA: Correction of metabolic acidosis and
its effect on albumin in chronic hemodialysis patients. Am J Kidney
Dis 31:35–40, 1998
36. Alvestrand A: Carbohydrate and insulin metabolism in renal
failure. Kidney Int 52 (Suppl 62):S48–S52, 1997
37. DeFronzo RA, Alvestrand A, Smith D, et al: Insulin resistance
in uremia. J Clin Invest 67:563–568, 1981
38. De Feo P, Gaisano MG, Haymond MW: Differential effects of
insulin deficiency on albumin and fibrinogen synthesis in humans.
J Clin Invest 88:833–840, 1991
39. Kaysen GA, Watson JB: Mechanism of hypoalbuminemia in the
7/8-nephrectomized rat with chronic renal failure. Am J Physiol
243:F372–F378, 1982
40. Kopple JD, Blumenkrantz MJ, Jones MR, et al: Plasma amino
acid levels and amino acid losses during continuous ambulatory
peritoneal dialysis. Am J Clin Nutr 36:395–402, 1982
41. Riedel E, Hampl H, Nundel M, et al: Essential branched-chain
amino acids and alpha-ketoanalogues in haemodialysis patients.
Nephrol Dial Transplant 7:117–120, 1992
42. Garibotto G, Paoletti E, Fiorini F, et al: Peripheral metabolism
of branched-chain keto acids in patients with chronic renal failure.
Miner Electrolyte Metab 19:25–31, 1993
43. Cupisti A, Langer K, Barsotti G: Plasma levels of branched chain
keto acids in nephrotic patients. Nephron 63:237, 1993
44. Swain LM, Shiota T, Walser M: Utilization for protein synthesis
of leucine and valine compared with their keto analogues. Am J
Clin Nutr 51:411–415, 1990
45. Kirsch RE, Frith LO, Saunders SJ: Stimulation of albumin syn-
thesis by keto analogues of amino acids. Biochim Biophys Acta
442:437–441, 1976
46. Mitch WE, Abras E, Walser M: Long-term effects of a new
Prinsen et al: Albumin and fibrinogen kinetics in CRF1504
ketoacid-amino acid supplement in patients with chronic renal
failure. Kidney Int 22:48–53, 1982
47. Mariani G, Barsotti G, Ciardella F, et al: Albumin metabolism
and nutritional status of uremic patients on a long-term very-low-
protein diet supplemented with essential amino acids and keto
analogues. J Nucl Med Allied Sci 28:237–244, 1984
48. Navarro JF, Mora C, Leon C, et al: Amino acid losses during
hemodialysis with polyacrylonitrile membranes: Effect of intradia-
lytic amino acid supplementation on plasma amino acid concentra-
tions and nutritional variables in nondiabetic patients. Am J Clin
Nutr 71:765–773, 2000
49. Jones M, Hagen T, Boyle CA, et al: Treatment of malnutrition
with 1.1% amino acid peritoneal dialysis solution: Results of a
multicenter outpatient study. Am J Kidney Dis 32:761–769, 1998
50. Kopple JD, Bernard D, Messana J, et al: Treatment of malnour-
ished CAPD patients with an amino acid based dialysate. Kidney
Int 47:1148–1157, 1995
